Close Menu

financial guidance

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Wall Street analysts have revised their revenue estimates for Complete Genomics following a company executive's updated guidance on genome shipments on Wednesday.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Danaher today reaffirmed its fourth quarter guidance for 2011 and initiated its outlook for 2012.

The firm's guidance came in below Wall Street expectations, sparking a drop in its shares.

The CEO of Calando parent firm Arrowhead Research also said that the RNAi shop has restarted preclinical research and development — a notable departure from events in 2009 when the company stopped all such work and shuttered Calando's lab amid a cash crunch.

The agency hopes the guidance can lay out a path for drug developers to identify PGx issues before a drug enters the market, instead of emerging PGx data changing the treatment's risk/benefit profile in the post-market setting.

Although the selection of the drug candidate marks the achievement of one of RXi's key goals for 2010, its other — the establishment of an industry partnership — isn't likely to be meet, based on a statement from a company official.

Lawrence Lesko, director of the Office of Clinical Pharmacology and Biopharmaceutics in FDA's Center for Drug Evaluation and Research, said that the agency is working on guidance documents for clinical pharmacogenomics, clinical trial enrichment, and internal standard operating procedures for cross-labeling efforts within FDA offices.


Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing. 

Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.

Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports. 

In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.